Last reviewed · How we verify
PN 400
At a glance
| Generic name | PN 400 |
|---|---|
| Sponsor | POZEN |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Proactive Management of Endoperitoneal Spread in Colonic Cancer (PHASE3)
- Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (PHASE3)
- Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome (NA)
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis (PHASE3)
- Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis (PHASE3)
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen (PHASE3)
- Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen (PHASE3)
- A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PN 400 CI brief — competitive landscape report
- PN 400 updates RSS · CI watch RSS
- POZEN portfolio CI